Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23539219 | 0.89 | MEN1 (0.41) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL28961660 | 0.88 | KMT2A (0.38) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL16118673 | 0.86 | MEN1 (0.46) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL24380748 | 0.86 | MEN1 (0.42) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL18038894 | 0.85 | KMT2A (0.41) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL19920585 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL30562194 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL16118624 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL21161662 | 0.83 | MEN1 (0.41) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL29525567 | 0.83 | MEN1 (0.37) | MEN1MAPK1KMT2AAPLNRDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | disclosed |
| US-11999728-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4267578-A1 | ESTROGEN RECEPTOR MODULATORS | Recurium IP Holdings, LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4247811-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11459315-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11339162-B1 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2022094244-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3707136-B1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3962906-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11242327-B2 | Analgesic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| CN-113302184-A | 1,3, 4-oxadiazolinone compounds and drugs | 日本新药株式会社 | 2021-08-24 | — | — | CN | disclosed |
| US-20210230148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2019204180-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459315-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | TPMT, TET1, TET2 | MEN1 1486/4885MAPK1 4022/4885KMT2A 91/4885 |
| US-11242327-B2 | Analgesic compounds | INA, IK, ACHE | MEN1 4009/4885MAPK1 3738/4885KMT2A 4218/4885 |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | MEN1 2/4885MAPK1 1106/4885KMT2A 6/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | MEN1 3264/4885MAPK1 884/4885KMT2A 3641/4885 |
| US-11339162-B1 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | MEN1 3713/4885MAPK1 849/4885KMT2A 3263/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | MEN1 4684/4885MAPK1 339/4885KMT2A 4179/4885 |
| US-11999728-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | MEN1 3713/4885MAPK1 849/4885KMT2A 3263/4885 |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP1B1, CYP7A1 | MEN1 2144/4885MAPK1 729/4885KMT2A 3732/4885 |
| US-20210230148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TPMT, TET1, TET2 | MEN1 1486/4885MAPK1 4022/4885KMT2A 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.